Wai Yuen Tong Medicine Holdings Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ching Ho Tang

Algemeen directeur

HK$23.6m

Totale compensatie

Percentage CEO-salaris	44.6%
Dienstverband CEO	6.6yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too

Jul 26

Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding

Mar 11

The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business

Dec 28

Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Jul 11

Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt

Jul 05

Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Mar 08

Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now

Aug 18

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Mar 17

Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares

Jan 22

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Dec 16

Analyse CEO-vergoeding

Hoe is Ching Ho Tang's beloning veranderd ten opzichte van Wai Yuen Tong Medicine Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	HK$24m	HK$11m	-HK$27m
Sep 30 2023	n/a	n/a	HK$36m
Jun 30 2023	n/a	n/a	HK$8m
Mar 31 2023	HK$16m	HK$15m	-HK$16m
Dec 31 2022	n/a	n/a	-HK$98m
Sep 30 2022	n/a	n/a	-HK$176m
Jun 30 2022	n/a	n/a	-HK$143m
Mar 31 2022	HK$9m	HK$8m	-HK$109m
Dec 31 2021	n/a	n/a	-HK$122m
Sep 30 2021	n/a	n/a	-HK$135m
Jun 30 2021	n/a	n/a	-HK$255m
Mar 31 2021	HK$8m	HK$8m	-HK$376m
Dec 31 2020	n/a	n/a	-HK$98m
Sep 30 2020	n/a	n/a	HK$179m
Jun 30 2020	n/a	n/a	HK$309m
Mar 31 2020	HK$15m	HK$12m	HK$439m
Dec 31 2019	n/a	n/a	HK$253m
Sep 30 2019	n/a	n/a	HK$66m
Jun 30 2019	n/a	n/a	HK$71m
Mar 31 2019	HK$14m	HK$12m	HK$75m
Dec 31 2018	n/a	n/a	HK$20m
Sep 30 2018	n/a	n/a	-HK$35m
Jun 30 2018	n/a	n/a	-HK$75m
Mar 31 2018	HK$13m	HK$12m	-HK$116m

Compensatie versus markt: De totale vergoeding ($USD 3.03M ) Ching Ho } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 233.82K ).

Compensatie versus inkomsten: De vergoeding van Ching Ho is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ching Ho Tang (62 yo)

6.6yrs

Tenure

HK$23,551,000

Compensatie

Mr. Ching Ho Tang, GBS, SBS, JP is Chairman of China Agri-Products Exchange Limited since February 8, 2021 and re-designated as its Executive Director since October 01, 2022. Mr. Tang Co-founded Wang On Gr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ching Ho Tang	Executive Chairman & MD	6.6yrs	HK$23.55m	geen gegevens
Wai Man Tang	Executive Director	6.6yrs	HK$2.20m	geen gegevens
Man Yee Law	Assistant GM of Purchasing Processing & Executive Director	3.8yrs	HK$909.00k	geen gegevens
Seung Ming Wong	Financial Controller	2.8yrs	geen gegevens	geen gegevens
Siu Fai Chan	Head of Factory Operations	3.2yrs	geen gegevens	geen gegevens
Yee Man Ng	Company Secretary	less than a year	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 897 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ching Ho Tang	Executive Chairman & MD	23.3yrs	HK$23.55m	geen gegevens
Wai Man Tang	Executive Director	6.6yrs	HK$2.20m	geen gegevens
Man Yee Law	Assistant GM of Purchasing Processing & Executive Director	3.8yrs	HK$909.00k	geen gegevens
Ka Fai Li	Independent Non-Executive Director	9.7yrs	HK$204.00k	geen gegevens
Wing Hang Sit	Independent Non-Executive Director	less than a year	HK$45.00k	geen gegevens
Wing Kwong Chan	Independent Non-Executive Director	less than a year	HK$45.00k	geen gegevens

5.2yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 897 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).

Wai Yuen Tong Medicine Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Wai Yuen Tong Medicine Holdings Limited Announces Board and Committee Changes

Wai Yuen Tong Medicine Holdings Limited Announces Changes of Company Secretary, with Effect from 1 April 2024

Wai Yuen Tong Medicine Holdings Limited Announces Change of Independent Non-Executive Directors and Change in Compositions of Board Committees

Wai Yuen Tong Medicine Holdings Limited, Annual General Meeting, Aug 22, 2023

Insufficient new directors

Wai Yuen Tong Medicine Holdings Limited, Annual General Meeting, Aug 26, 2022

Recent updates

Wai Yuen Tong Medicine Holdings Limited Announces Board and Committee Changes

New major risk - Share price stability

Wai Yuen Tong Medicine Holdings Limited Approves Final Cash Dividend for the Year Ended 31 March, 2024

Upcoming dividend of HK$0.18 per share

Full year 2024 earnings released: HK$0.023 loss per share (vs HK$0.014 loss in FY 2023)

Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too

New major risk - Revenue and earnings growth

Full year 2024 earnings released: HK$0.023 loss per share (vs HK$0.017 loss in FY 2023)

Wai Yuen Tong Medicine Holdings Limited Proposes Final Dividend for the Year Ended March 31, 2024, Payable on 06 September 2024

Wai Yuen Tong Medicine Holdings Limited Proposes Special Dividend, Payable on 06 September 2024

Wai Yuen Tong Medicine Holdings Limited to Report Fiscal Year 2024 Results on Jun 26, 2024

Wai Yuen Tong Medicine Holdings Limited Announces Changes of Company Secretary, with Effect from 1 April 2024

Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding

The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business

Wai Yuen Tong Medicine Holdings Limited Announces Change of Independent Non-Executive Directors and Change in Compositions of Board Committees

First half 2024 earnings released: EPS: HK$0.003 (vs HK$0.043 loss in 1H 2023)

Wai Yuen Tong Medicine Holdings Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.017 loss per share (vs HK$0.088 loss in FY 2022)

Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

Full year 2023 earnings released: HK$0.017 loss per share (vs HK$0.088 loss in FY 2022)

Wai Yuen Tong Medicine Holdings Limited, Annual General Meeting, Aug 22, 2023

New minor risk - Financial data availability

Wai Yuen Tong Medicine Holdings Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

Wai Yuen Tong Medicine Holdings Limited Provides Earnings Guidance for the Financial Year Ended 31 March 2023

Lei Wa entered into the Provisional Agreement to acquire Billion Good Investment Limited from Wai Yuen Tong Medicine Holdings Limited (SEHK:897) and Wang On (Nominees) Limited for HKD 71 million.

First half 2023 earnings released: HK$0.043 loss per share (vs HK$0.011 profit in 1H 2022)

Wai Yuen Tong Medicine Holdings Limited to Report First Half, 2023 Results on Nov 25, 2022

Insufficient new directors

Wai Yuen Tong Medicine Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Wai Yuen Tong Medicine Holdings Limited, Annual General Meeting, Aug 26, 2022

Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt

Full year 2022 earnings released: HK$0.088 loss per share (vs HK$0.30 loss in FY 2021)

Wai Yuen Tong Medicine Holdings Limited to Report Fiscal Year 2022 Results on Jun 28, 2022

Wai Yuen Tong Medicine Holdings Limited Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Financial Year Ended March 31, 2022

Insufficient new directors

Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now

Full year 2021 earnings released: HK$0.30 loss per share (vs HK$0.078 profit in FY 2020)

Wai Yuen Tong Medicine Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended March 31, 2021

Executive Director has left the company

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

New 90-day low: HK$0.34

Executive Director has left the company

Wai Yuen Tong Medicine Holdings Limited Announces Executive Changes

Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares

First half 2021 earnings released: HK$0.19 loss per share

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

New 90-day high: HK$0.41

First half 2021 earnings released: HK$0.19 loss per share

Wai Yuen Tong Medicine Holdings Limited Announces Resignation of Mak Yuen Ming, Anita as Company Secretary

New 90-day high: HK$0.33

New 90-day high - HK$0.30

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd